Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Mantle-Cell 9Recurrence 5Lymphoma 4Lymphoma, B-Cell 3Dendritic Cell Sarcoma, Interdigitating 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytokine Release Syndrome 1Aggression 1

Interventions

Cyclophosphamide 46fludarabine phosphate 24Busulfan 22Peripheral Blood Stem Cell Transplantation 20Radiotherapy 19Filgrastim 19Mycophenolic Acid 18Antilymphocyte Serum 18Cyclosporine 17Whole-Body Irradiation 16Rituximab 16Etoposide 16Methotrexate 15Melphalan 15Methylprednisolone 14Tacrolimus 12Cytarabine 12Vincristine 10Prednisone 10Doxorubicin 10Cord Blood Stem Cell Transplantation 10Thiotepa 6Granulocyte Colony-Stimulating Factor 6Leucovorin 5sargramostim 4fludarabine 4Daunorubicin 4glofitamab 3Sirolimus 3Methylprednisolone Hemisuccinate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Dendritic Cell Sarcoma, Interdigitating × glofitamab × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07326371 2026-01-08

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Ruijin Hospital

Phase 2 Not yet recruiting
24 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡